印度最高法院在3月决定所有血库是否必须使用NAT测试来预防艾滋病毒、乙型肝炎和丙型肝炎通过输血传播。 India’s Supreme Court to decide in March whether all blood banks must use NAT testing to prevent HIV, hepatitis B and C transmission via transfusions.

印度最高法院将于3月审查是否所有血库都必须采用强制性核酸测试(NAT)来检测艾滋病毒、乙型肝炎和丙型肝炎以及其他输血传染病。 India’s Supreme Court will examine in March whether all blood banks must adopt mandatory Nucleic Acid Testing (NAT) to detect HIV, hepatitis B and C, and other transfusion-transmissible infections. 由首席大法官Surya Kant和法官Joymalya Bagchi和法官Vipul M Pancholi领导的法院正在审查一项公共利益诉讼,以儿童可预防感染和必须维护安全血液权为由,敦促全国实施国家打击人口贩运方案。 The court, led by Chief Justice Surya Kant and Justices Joymalya Bagchi and Vipul M Pancholi, is reviewing a Public Interest Litigation urging nationwide NAT implementation, citing preventable infections in children and the need to uphold the right to safe blood. 请愿人辩称,比目前方法早于检测病毒遗传材料的NAT对保护地中海贫血患者等脆弱病人至关重要,特别是在2023年和2025年政府医院通过输血传播艾滋病毒和肝炎后。 The petitioners argue NAT, which detects viral genetic material earlier than current methods, is essential to protect vulnerable patients like Thalassemia sufferers, especially after multiple cases of HIV and hepatitis transmission via blood transfusions in government hospitals in 2023 and 2025. 法院要求获得关于政府设施中NAT成本和无障碍环境的详细数据,引起人们对整个印度保健系统的财政可行性和可扩展性的关切。 The court has asked for detailed data on NAT costs and accessibility in government facilities, raising concerns about financial feasibility and scalability across India’s healthcare system.